Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations

Area of Science:

• Developmental biology
• Teratology
• Medical history

Background:

• Thalidomide caused severe limb defects (embryopathy) when used in the 1950s-60s.
• Despite its withdrawal, thalidomide is now re-licensed for specific conditions like cancers and inflammatory disorders.
• Unsafe use can still lead to embryonic damage.

Purpose of the Study:

• To provide a comprehensive review of thalidomide upper limb embryopathy.
• To discuss pathogenesis, historical and current management strategies for pediatric and adult patients.
• To raise awareness of age-related changes in individuals with limb differences and inform care.

Main Methods:

• Literature review of thalidomide embryopathy.
• Analysis of historical and contemporary management approaches.
• Examination of age-related changes and future therapeutic directions.

Main Results:

• Thalidomide's teratogenic effects on limb development are well-documented.
• Current thalidomide use requires strict safety protocols to prevent embryo exposure.
• Thalidomide analogues with reduced teratogenicity show promise.

Conclusions:

• Understanding thalidomide embryopathy is crucial for managing survivors.
• Awareness of age-related issues aids surgical and medical support for limb differences.
• Principles of care for thalidomide survivors can inform management of other congenital limb differences.